Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Magenta Therapeutics, Inc is a biotechnology business based in the US. Magenta Therapeutics shares (MGTA) are listed on the NASDAQ and all prices are listed in US Dollars. Magenta Therapeutics employs 70 staff and has a market cap (total outstanding shares value) of USD$314.5 million.
|52-week range||USD$5.76 - USD$16.19|
|50-day moving average||USD$6.8739|
|200-day moving average||USD$7.7775|
|Wall St. target price||USD$16.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.908|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-29.94%|
|Return on equity TTM||-49.99%|
|Market capitalisation||USD$314.5 million|
TTM: trailing 12 months
There are currently 1.9 million Magenta Therapeutics shares held short by investors – that's known as Magenta Therapeutics's "short interest". This figure is 16.1% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Magenta Therapeutics shares can be evaluated.
Magenta Therapeutics's "short interest ratio" (SIR) is the quantity of Magenta Therapeutics shares currently shorted divided by the average quantity of Magenta Therapeutics shares traded daily (recently around 184070.41420118). Magenta Therapeutics's SIR currently stands at 10.14. In other words for every 100,000 Magenta Therapeutics shares traded daily on the market, roughly 10140 shares are currently held short.
However Magenta Therapeutics's short interest can also be evaluated against the total number of Magenta Therapeutics shares, or, against the total number of tradable Magenta Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Magenta Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Magenta Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0629% of the tradable shares (for every 100,000 tradable Magenta Therapeutics shares, roughly 63 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Magenta Therapeutics.
Find out more about how you can short Magenta Therapeutics stock.
We're not expecting Magenta Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Magenta Therapeutics's shares have ranged in value from as little as $5.76 up to $16.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magenta Therapeutics's is 2.5611. This would suggest that Magenta Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.